MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfusions.
Information source: Sheba Medical Center
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Iron Overload
Phase: N/A
Status: Recruiting
Sponsored by: Sheba Medical Center Official(s) and/or principal investigator(s):
Orly Goitein, MD, Principal Investigator, Affiliation: Sheba Medical Center
Summary
Sickle cell anemia and Sickle cell β thalassemia patients require multiple transfusions in
order to avoid chronic anemia sequel. This regimen entails intrinsic deleterious effects, the
majority of which are related to iron deposition in the reticuloendothelial system. Thus,
iron is deposited in hepatic, myocardial and endocrine glands tissues. Tools available for
iron load evaluation include serum ferrtin levels, liver biopsy and echocardiography, all
are non specific.
The purpose of this work is to compare iron overload in the liver, heart and pancreas in
Sickle cell anemia and Sickle cell β thalassemia patients using T2* MRI sequences.
Clinical Details
Official title: Evaluation of Iron Overload in the Heart, Liver and Pancreas: Patients With Sickle β Thalassemia and Sickle Cell Anemia.
Study design: Case Control, Prospective
Primary outcome: outcome measure: iron overload on T2* MRI in the heart , liver and pancreas.
Detailed description:
Sickle cell anemia and Sickle cell β thalassemia patients recieving multiple transfusions are
exposed to the effects of iron deposition in the reticuloendothelial system, including
cardiac muscle, liver and pancreas. Tools available for iron load evaluation include serum
ferrtin levels, liver biopsy and echocardiography, all are non specific.
The purpose of this work is to compare iron overload in the liver, heart and pancreas in
Sickle cell anemia and Sickle cell β thalassemia patients using T2* MRI sequences.
Patients and Methods: 27 Sickle cell anemia and 28 Sickle cell β thalassemia will undergo
transthoracic echocardiography, cardiac MRI using T2* sequences and clinical and laboratory
evaluation for iron overload including ferritin levels and oral glucose tolerance test
.
Eligibility
Minimum age: 18 Years.
Maximum age: 35 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- clinical diagnosis of Sickle cell anemia or Sickle cell β thalassemia having received
multiple blood transfusions.
Exclusion Criteria:
- contraindication to MRI
Locations and Contacts
Sheba Medical Center , Imaging Dept, Tel Hashomer 52621, Israel; Recruiting
Orly Goitein, MD, Phone: 972-52-6666681, Email: orly.goitein@sheba.health.gov.il
Shimrit Skop, Phone: 972-3-530-2530, Email: shimrit.skop@sheba.health.gov.il
Orly Goitein, MD, Principal Investigator
Additional Information
Starting date: January 2008
Ending date: February 2008
Last updated: February 25, 2008
|
